A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

This study is only open to people who have already taken part in the earlier 'parent' study (Study B7981040). You must have completed the full 52 weeks of treatment in that first study for non-segmental vitiligo. Your first visit for this new trial must take place within 30 days of finishing the previous one.

Participants must be aged 18 or older, or aged 12 to 17 where local health authorities and ethics committees have approved adolescent participation. Both active vitiligo (patches that are still spreading) and stable vitiligo are included.

You will not be able to take part if you had to leave the earlier study early due to health or safety concerns. You also cannot join if you have serious blood test abnormalities or current thoughts of self-harm or suicide, as safety is the top priority.

Taking part in this study lasts for up to 60 weeks in total. During this time, you will visit the study clinic approximately 9 times. At these visits, the study team will carry out health checks, such as examining your skin patches, taking blood samples, and asking how you are feeling.

You will take one capsule by mouth every day at home for up to 52 weeks. Depending on which group you are placed in, your capsule will contain ritlecitinib (50 mg or 100 mg) or a placebo (a lookalike capsule with no active medicine). On the days you have a clinic appointment, you will need to wait and take your daily capsule at the clinic instead of at home. After finishing treatment, there will be a follow-up period to check on your health.